Skip to main content
. 2011 May 20;11:4. doi: 10.1186/1472-6904-11-4

Table 4.

Treatment persistence

Persistence

3 months 6 months 12 months
ACE 83.6% 75.3% 64.5%

ARB 84.8% 77.5% 66.3%

β-blockers 86.3% 80.0% 70.4%

Spironolactone 76.3%* 65.3%* 50.7%*

* Spironolactone versus ACE, ARB and β-blockers: p < 0.001 (Pearson's chi square test)